From: Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage
Influence on outcomes | Effect on endoscopic ulcers | Effect on upper gastrointestinal bleeding |
---|---|---|
Risk factors | Â | Â |
Age | RCTs show incidence of ulcers to increase with age, more than threefold over five decades | Patients over 75 years old, 2.5-fold increased risk of upper gastrointestinal complications |
History of previous ulcer or bleeding | Previous history increases risk of ulcer fourfold in RCTs | Previous history increases risk of bleeding fivefold in RCTs; observational studies support this |
Helicobacter pylori | Meta-analysis of RCTs shows 60% decrease in ulcers | Meta-analysis of RCTs shows 80% decrease in ulcers |
Aspirin alone | Dose-related increase in ulcers over range of 81 to 325 mg daily | Low-dose aspirin is associated with increased risk of bleeding events |
Aspirin plus coxibs or NSAIDs | Low-dose aspirin increases ulcer rates with placebo, coxib, and NSAID in RCTs | Low-dose aspirin increases bleeding rates when added to coxibs or NSAIDs |
Ulcer prevention strategies used with NSAIDs | Â | |
Misoprostol | Misoprostol reduced ulcers by 70% in a meta-analysis of RCTs | Misoprostol reduced bleeds by 40% in a meta-analysis of RCTs |
Histamine-2 receptor antagonists | Histamine-2 receptor antagonist therapy reduced ulcers by 60% in a meta-analysis of RCTs | Histamine-2 receptor antagonist therapy reduced bleeds by 30 to 40% in two observational studies |
Proton pump inhibitors | Proton pump inhibitor therapy reduced ulcers by 60% in a meta-analysis of RCTs | Observational studies support reduced risk of upper gastrointestinal complications and bleeding with proton pump inhibitor |
Coxib use | Pooled analysis across RCTs indicates that coxibs reduce ulcers by about 70% compared with NSAIDs | Pooled analysis across RCTs indicates about a 40 to 50% reduction in ulcer complications with coxibs; observational studies show a consistent 50% reduction or more in upper gastrointestinal bleeding events |